Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol
Autor(a) principal: | |
---|---|
Data de Publicação: | 2005 |
Outros Autores: | , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | São Paulo medical journal (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000600003 |
Resumo: | CONTEXT AND OBJECTIVE: Liposomal daunorubicin has been used to treat hematological malignancies, including multiple myeloma (MM). The goal was to evaluate efficacy, side-effects and toxicity of liposomal daunorubicin and dexamethasone ("DD Protocol"). DESIGN AND SETTING: Prospective study at Sírio-Libanês, São Camilo, Brasil and Alemão Oswaldo Cruz hospitals. METHODS: Twenty consecutive patients with active MM received four cycles of liposomal daunorubicin intravenously for two hours (25-30 mg/m²/day) on three consecutive days per month, with oral dexamethasone (10 mg every six hours) on four consecutive days three times a month. RESULTS: The male/female ratio was 1:1 and median age 60. Nine patients were stage IIA, ten IIIA and one IIIB. The median from diagnosis to starting DD was 13 months. All patients received four cycles, except one. Fifteen had already received chemotherapy before DD. Responses of > 50% reduction in serum monoclonal paraprotein were observed in six patients after first cycle (30%), six after second (30%) and four after third (20%), while four (20%) did not obtain this. Initially, 17 patients (85%) had anemia: 12 (70%) achieved correction. Progressive disease was observed in three patients (15%), while one had minimal response, four (20%) partial and 12 (60%) complete. Hematological toxicity was acceptable: three patients (15%) had neutrophils < 1,000/mm³; none had thrombocytopenia. Gastrointestinal toxicity was mild: nausea (10%), anorexia (15%) and no vomiting. CONCLUSIONS: This treatment has mild toxicity and good response rate. It may therefore be feasible before autologous bone marrow transplantation. |
id |
APM-1_5c3bbf0e35add9fe37922b903023c365 |
---|---|
oai_identifier_str |
oai:scielo:S1516-31802005000600003 |
network_acronym_str |
APM-1 |
network_name_str |
São Paulo medical journal (Online) |
repository_id_str |
|
spelling |
Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD ProtocolMultiple myelomaDaunorubicinDexamethasoneDrug therapyDrug toxicityCONTEXT AND OBJECTIVE: Liposomal daunorubicin has been used to treat hematological malignancies, including multiple myeloma (MM). The goal was to evaluate efficacy, side-effects and toxicity of liposomal daunorubicin and dexamethasone ("DD Protocol"). DESIGN AND SETTING: Prospective study at Sírio-Libanês, São Camilo, Brasil and Alemão Oswaldo Cruz hospitals. METHODS: Twenty consecutive patients with active MM received four cycles of liposomal daunorubicin intravenously for two hours (25-30 mg/m²/day) on three consecutive days per month, with oral dexamethasone (10 mg every six hours) on four consecutive days three times a month. RESULTS: The male/female ratio was 1:1 and median age 60. Nine patients were stage IIA, ten IIIA and one IIIB. The median from diagnosis to starting DD was 13 months. All patients received four cycles, except one. Fifteen had already received chemotherapy before DD. Responses of > 50% reduction in serum monoclonal paraprotein were observed in six patients after first cycle (30%), six after second (30%) and four after third (20%), while four (20%) did not obtain this. Initially, 17 patients (85%) had anemia: 12 (70%) achieved correction. Progressive disease was observed in three patients (15%), while one had minimal response, four (20%) partial and 12 (60%) complete. Hematological toxicity was acceptable: three patients (15%) had neutrophils < 1,000/mm³; none had thrombocytopenia. Gastrointestinal toxicity was mild: nausea (10%), anorexia (15%) and no vomiting. CONCLUSIONS: This treatment has mild toxicity and good response rate. It may therefore be feasible before autologous bone marrow transplantation.Associação Paulista de Medicina - APM2005-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000600003Sao Paulo Medical Journal v.123 n.6 2005reponame:São Paulo medical journal (Online)instname:Associação Paulista de Medicinainstacron:APM10.1590/S1516-31802005000600003info:eu-repo/semantics/openAccessDulley,Frederico LuizSaboya,RosauraHungria,Vânia Tietsche de MoraesBueno,Nadjanara DornaMello,Fernando Gomes deFrota,Maria TerezaChiattone,Carlos SergioBarros,José CarlosMori,Nair SumieSturaro,DanielMacedo,Maria Cristina Martins de AlmeidaSilva,Roberto Luiz daMelo,Leila Maria Magalhães Pessoa deSouza,Cármino Antonioeng2006-01-20T00:00:00Zoai:scielo:S1516-31802005000600003Revistahttp://www.scielo.br/spmjhttps://old.scielo.br/oai/scielo-oai.phprevistas@apm.org.br1806-94601516-3180opendoar:2006-01-20T00:00São Paulo medical journal (Online) - Associação Paulista de Medicinafalse |
dc.title.none.fl_str_mv |
Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol |
title |
Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol |
spellingShingle |
Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol Dulley,Frederico Luiz Multiple myeloma Daunorubicin Dexamethasone Drug therapy Drug toxicity |
title_short |
Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol |
title_full |
Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol |
title_fullStr |
Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol |
title_full_unstemmed |
Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol |
title_sort |
Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol |
author |
Dulley,Frederico Luiz |
author_facet |
Dulley,Frederico Luiz Saboya,Rosaura Hungria,Vânia Tietsche de Moraes Bueno,Nadjanara Dorna Mello,Fernando Gomes de Frota,Maria Tereza Chiattone,Carlos Sergio Barros,José Carlos Mori,Nair Sumie Sturaro,Daniel Macedo,Maria Cristina Martins de Almeida Silva,Roberto Luiz da Melo,Leila Maria Magalhães Pessoa de Souza,Cármino Antonio |
author_role |
author |
author2 |
Saboya,Rosaura Hungria,Vânia Tietsche de Moraes Bueno,Nadjanara Dorna Mello,Fernando Gomes de Frota,Maria Tereza Chiattone,Carlos Sergio Barros,José Carlos Mori,Nair Sumie Sturaro,Daniel Macedo,Maria Cristina Martins de Almeida Silva,Roberto Luiz da Melo,Leila Maria Magalhães Pessoa de Souza,Cármino Antonio |
author2_role |
author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Dulley,Frederico Luiz Saboya,Rosaura Hungria,Vânia Tietsche de Moraes Bueno,Nadjanara Dorna Mello,Fernando Gomes de Frota,Maria Tereza Chiattone,Carlos Sergio Barros,José Carlos Mori,Nair Sumie Sturaro,Daniel Macedo,Maria Cristina Martins de Almeida Silva,Roberto Luiz da Melo,Leila Maria Magalhães Pessoa de Souza,Cármino Antonio |
dc.subject.por.fl_str_mv |
Multiple myeloma Daunorubicin Dexamethasone Drug therapy Drug toxicity |
topic |
Multiple myeloma Daunorubicin Dexamethasone Drug therapy Drug toxicity |
description |
CONTEXT AND OBJECTIVE: Liposomal daunorubicin has been used to treat hematological malignancies, including multiple myeloma (MM). The goal was to evaluate efficacy, side-effects and toxicity of liposomal daunorubicin and dexamethasone ("DD Protocol"). DESIGN AND SETTING: Prospective study at Sírio-Libanês, São Camilo, Brasil and Alemão Oswaldo Cruz hospitals. METHODS: Twenty consecutive patients with active MM received four cycles of liposomal daunorubicin intravenously for two hours (25-30 mg/m²/day) on three consecutive days per month, with oral dexamethasone (10 mg every six hours) on four consecutive days three times a month. RESULTS: The male/female ratio was 1:1 and median age 60. Nine patients were stage IIA, ten IIIA and one IIIB. The median from diagnosis to starting DD was 13 months. All patients received four cycles, except one. Fifteen had already received chemotherapy before DD. Responses of > 50% reduction in serum monoclonal paraprotein were observed in six patients after first cycle (30%), six after second (30%) and four after third (20%), while four (20%) did not obtain this. Initially, 17 patients (85%) had anemia: 12 (70%) achieved correction. Progressive disease was observed in three patients (15%), while one had minimal response, four (20%) partial and 12 (60%) complete. Hematological toxicity was acceptable: three patients (15%) had neutrophils < 1,000/mm³; none had thrombocytopenia. Gastrointestinal toxicity was mild: nausea (10%), anorexia (15%) and no vomiting. CONCLUSIONS: This treatment has mild toxicity and good response rate. It may therefore be feasible before autologous bone marrow transplantation. |
publishDate |
2005 |
dc.date.none.fl_str_mv |
2005-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000600003 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000600003 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S1516-31802005000600003 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Paulista de Medicina - APM |
publisher.none.fl_str_mv |
Associação Paulista de Medicina - APM |
dc.source.none.fl_str_mv |
Sao Paulo Medical Journal v.123 n.6 2005 reponame:São Paulo medical journal (Online) instname:Associação Paulista de Medicina instacron:APM |
instname_str |
Associação Paulista de Medicina |
instacron_str |
APM |
institution |
APM |
reponame_str |
São Paulo medical journal (Online) |
collection |
São Paulo medical journal (Online) |
repository.name.fl_str_mv |
São Paulo medical journal (Online) - Associação Paulista de Medicina |
repository.mail.fl_str_mv |
revistas@apm.org.br |
_version_ |
1754209261292879872 |